Sanofi (NASDAQ:SNY) Short Interest Update

Sanofi (NASDAQ:SNY) was the target of a significant growth in short interest in January. As of January 15th, there was short interest totalling 5,290,000 shares, a growth of 25.7% from the December 31st total of 4,210,000 shares. Based on an average daily volume of 2,420,000 shares, the short-interest ratio is currently 2.2 days. Currently, 0.2% of the shares of the stock are short sold.

Sanofi Price Performance

NASDAQ SNY traded down $0.99 during trading hours on Monday, hitting $53.35. 1,890,724 shares of the company’s stock traded hands, compared to its average volume of 2,654,421. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 0.74. The company has a market capitalization of $135.39 billion, a PE ratio of 21.43, a PEG ratio of 1.26 and a beta of 0.57. The firm’s 50-day moving average is $49.24 and its 200-day moving average is $52.30. Sanofi has a 52-week low of $45.22 and a 52-week high of $58.97.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.58%. Equities analysts forecast that Sanofi will post 4.34 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

SNY has been the subject of several research reports. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research note on Thursday. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday. Finally, StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Two analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $60.00.

Hedge Funds Weigh In On Sanofi

Institutional investors and hedge funds have recently bought and sold shares of the company. Northwest Investment Counselors LLC acquired a new position in shares of Sanofi in the 3rd quarter worth approximately $29,000. Synergy Asset Management LLC acquired a new position in shares of Sanofi in the 4th quarter worth approximately $25,000. Concord Wealth Partners lifted its holdings in shares of Sanofi by 157.8% in the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after acquiring an additional 363 shares during the last quarter. McClarren Financial Advisors Inc. lifted its holdings in shares of Sanofi by 952.6% in the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after acquiring an additional 543 shares during the last quarter. Finally, Sunbelt Securities Inc. lifted its holdings in shares of Sanofi by 72.1% in the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after acquiring an additional 313 shares during the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.